Human Vaccines & Immunotherapeutics
Volume 19, 2023 - Issue 1
Zoster
How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Ru Hana Value Evidence Outcome Department, GSK, Wavre, BelgiumCorrespondence[email protected]
https://orcid.org/0000-0002-4851-1462View further author information
https://orcid.org/0000-0002-4851-1462View further author information, Jorge A. Gomezb Value Evidence Outcome Department, GSK, Buenos Aires, Argentinahttps://orcid.org/0000-0001-5459-4973View further author information
https://orcid.org/0000-0001-5459-4973View further author information, Bruna de Verasc Value Evidence Outcome Department, GSK, Rio de Janeiro, Brazilhttps://orcid.org/0000-0002-7927-050XView further author information
https://orcid.org/0000-0002-7927-050XView further author information, Thatiana Pintoa Value Evidence Outcome Department, GSK, Wavre, Belgiumhttps://orcid.org/0000-0002-0957-3118View further author information
https://orcid.org/0000-0002-0957-3118View further author information, Adriana Guzman-Holsta Value Evidence Outcome Department, GSK, Wavre, Belgiumhttps://orcid.org/0000-0002-6753-2541View further author information
https://orcid.org/0000-0002-6753-2541View further author information, Javier Nietod Medical Affairs Department, GSK, Panama City, Panamahttps://orcid.org/0000-0002-3073-2830View further author information
https://orcid.org/0000-0002-3073-2830View further author information & Désirée A. M. van Oorschota Value Evidence Outcome Department, GSK, Wavre, Belgiumhttps://orcid.org/0000-0002-0382-0333View further author information
https://orcid.org/0000-0002-0382-0333View further author information show all